31P-MRS and Huntington Disease

Not Applicable

Completed

• Conditions: Huntington Disease
• Interventions: Other: 31P-MR spectroscopy; Other: 31P-RMN spectroscopy

• Registration Number: NCT01359774
• Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary

The purpose of this study is to identify and quantify a brain energy deficit in Huntington patients, using 31P-RMN spectroscopy.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-04
• Study First Submitted: 2011-05-23
• Study First Submitted QC: 2011-05-23
• Study First Posted: 2011-05-25
• Primary Completion: 2012-04
• Study Completion: 2012-04
• Status Verified: 2012-09
• Last Update Submitted: 2012-09-20
• Last Update Posted: 2012-09-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• 5<UHDRS<50
• Age>18 years
• Ability to undergo MR scanning
• Covered by french social security

Exclusion Criteria

• Evidence of psychiatric disorder
• Attendant neurological disorder
• Contraindications to MRI (claustrophobia, metallic or material implants)
• Severe head injury
• Unable to understand the protocol
• Pregnancy
• Failure to give informed consent
• Subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent)
• Unwillingness to be informed in case of abnormal MRI

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Healthy volunteers	31P-MR spectroscopy	-
Huntington patients	31P-RMN spectroscopy	-

Primary Outcome Measures

Name	Time	Method
Brain energy deficit in Huntington patients	one year	31P-MRS allows quantification of high-energy phosphate metabolites such as ATP and phosphocreatine.; Objective: to look at brain energy metabolism during rest and activation.

Secondary Outcome Measures

Name	Time	Method
Correlating a brain energy deficit with (i) biochemical parameters and (ii) clinical parameters in Huntington patients	one year	Biochemical parameters include metabolites that we previously showed to be biomarkers in HD: branched chain amino acids and IGF1.; Clinical parameters include UHDRS and TFC.

Trial Locations

Locations (1)

Hopital de la Pitié-Salpetrière; 🇫🇷 Paris, France